Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Show full item record



Permalink

http://hdl.handle.net/10138/321499

Citation

Shimoni , A , Labopin , M , Savani , B , Byrne , M , Volin , L , Finke , J , Niederwieser , D , Ehninger , G , Blaise , D , Beelen , D , Tabrizi , R , Sengeloev , H , Ganser , A , Cornelissen , J J , Mohty , M & Nagler , A 2019 , ' Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation ' , Biology of Blood and Marrow Transplantation , vol. 25 , no. 11 , pp. 2251-2260 . https://doi.org/10.1016/j.bbmt.2019.06.031

Title: Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Author: Shimoni, Avichai; Labopin, Myriam; Savani, Bipin; Byrne, Michael; Volin, Liisa; Finke, Jurgen; Niederwieser, Dietger; Ehninger, Gerhard; Blaise, Didier; Beelen, Dietrich; Tabrizi, Reza; Sengeloev, Henrik; Ganser, Arnold; Cornelissen, Jan J.; Mohty, Mohamad; Nagler, Arnon
Contributor: University of Helsinki, HUS Comprehensive Cancer Center
Date: 2019-11
Language: eng
Number of pages: 10
Belongs to series: Biology of Blood and Marrow Transplantation
ISSN: 1083-8791
URI: http://hdl.handle.net/10138/321499
Abstract: Allogeneic stem cell transplantation (SCT) is potentially curative therapy in acute myeloid leukemia (AML). Marked improvement has been achieved with SCT from matched unrelated donors (MUDS) in recent years. However, there are limited data comparing the long-term outcomes (beyond 10 years) after SCT from sibling donors and MUDs in older patients with AML. We analyzed these outcomes in a large cohort of patients with AML (n = 1134), age >= 50 years, who were alive and leukemia-free 2 years after SCT from matched siblings (n = 848) or MUDs (n = 286), with a median follow-up of 8.9 years. The median age was 56 and 58 years after SCT from siblings and MUDs, respectively (P=.005). In the sibling group, 77%, 12%, and 11% were in first complete remission (CR1), second complete remission (CR2), and active leukemia at SCT compared with 50%, 25%, and 25% in the MUD group, respectively (P
Subject: 3122 Cancers
Acute myeloid leukemia
Allogeneic stem cell transplantation
long-term outcome
Sibling
UNRELATED DONOR
Acute myeloid leukemia
Allogeneic stem cell transplantation
Long-term outcome
Sibling
Unrelated donor
REDUCED-INTENSITY
CONDITIONING REGIMEN
IDENTICAL SIBLINGS
LATE DEATHS
SURVIVAL
AML
ADULTS
MORTALITY
SUPERIOR
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Comparable_Long ... ts_Older_than_50_years.pdf 729.5Kb PDF View/Open
1_s2.0_S108387911930415X_main.pdf 861.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record